Chemotherapy dose delays

Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chem‑ otherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate. Thus, rapid recovery and continuous maintenance of platelet count during chemotherapy cycles are crucial in patients with CIT.

15p visharma 20-10-2023 6 2   Download

An uninterrupted dose of oxaliplatin-based cytotoxic therapy is an essential component in the standard treatment regimen of metastatic colon cancer (mCC). Data on the impacts of dose intensity reduction on the palliative treatment for patients with mCC remain scarce.

11p viangelamerkel 27-07-2022 7 2   Download

Ovarian cancer is a common gynaecological malignancy still remaining a challenge to treat. The objective of this study was to evaluate the impact of platinum dose reduction and chemotherapy delays on progression free survival and overall survival in patients with stage III ovarian cancer and to analyze reasons for such chemotherapy scheme modifications.

8p vialabama2711 21-09-2020 39 1   Download

APF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h) chemotherapy-induced nausea and vomiting (CINV). In a phase III trial, APF530 was noninferior to palonosetron in preventing acute CINV following single-dose moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV in MEC (MEC and HEC defined by Hesketh criteria).

10p vinaypyidaw2711 26-08-2020 15 2   Download

Better surgical techniques, chemotherapy and biological therapy have improved survival in patients with colorectal cancer (CRC), most markedly in younger patients. About half of patients over 70 years receive dose reductions or early treatment discontinuation of the planned adjuvant or first-line treatment due to side effects.

9p vidhaka2711 31-07-2020 10 2   Download

The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications.

9p vibaku2711 22-07-2020 13 2   Download

Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.

8p viputrajaya2711 22-06-2020 9 1   Download

Primary prophylaxis (i.e., shortly after completing chemotherapy to reduce the nadir) of G-CSF to patients receiving cytotoxic regimens is associated with a 20% incidence of febrile neutropenia. "Dose-dense" regimens, where cycling of chemotherapy is intended to be completed without delay of administered doses, may also benefit, but such patients should be on a clinical trial. Administration of G-CSF in these circumstances has reduced the incidence of febrile neutropenia in several studies by about 50%.

5p konheokonmummim 03-12-2010 49 3   Download

Table 81-2 Commonly Used Cancer Chemotherapy Agents Drug Exam ples of Usual Doses Toxicity Issues Interactions, Direct DNA-Interacting Agents Alkylators Cyclophospha 2000 400– mg/m2 Marrow (relative Liver metabolism required mide IV platelet sparing) to activate to phosphoramide 100 mg/m2 PO qd Common alkylatora Mesna protects Cardiac dose) against Cystitis mustard + acrolein (high "high-dose" bladder damage Mechloretha mine 6 mg/m2 IV day Marrow Topical use in cutaneous lymphoma Vesicant 1 and day 8 Nausea Chlorambucil 1–3 mg/m2 qd PO Marrow Common alkylatora ...

28p konheokonmummim 03-12-2010 67 2   Download